Litcius/Paper detail

Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis

Nikolaj Frost, Tamar Zhamurashvili, Maximilian von Laffert, Frederick Klauschen, Christoph Ruwwe‐Glösenkamp, Matthias Raspe, Matthias Brunn, Sebastian Ochsenreither, Bettina Temmesfeld‐Wollbrück, Norbert Suttorp, Christian Grohé, Martin Witzenrath

2020Clinical Lung Cancer54 citationsDOI

Topics & Concepts

MedicinePemetrexedOncologyInternal medicineLung cancerAdenocarcinomaChemotherapyLungCancerCisplatinLung Cancer Treatments and MutationsThyroid Cancer Diagnosis and TreatmentLung Cancer Diagnosis and Treatment
Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis | Litcius